 Meridian Bioscience Inc NASDAQ: VIVO reported a 30 increase in Q2 sales to 111.2 million, the highest in the companys history, with both segments ahead of expectations, beating the consensus of 99.54 million. Revenues from the life science division grew 32 YY to 70.1 million. 